WebCLNP023B12301. Pediatrics Nephrology Kidney Disease Adult Subjects The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy. VT-001-0050 Atacicept IgA Nephropathy ORIGIN ... WebCLNP023B12301 : Brief Title: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G) Official Title: A Multicenter, Randomized, Double-blind, …
European Medicines Agency decision
WebCLNP023B12301 is a Phase 3 pivotal trial for registration of iptacopan in C3G. The study aims to determine the reduction in UPCR and improvement in eGFR in participants … WebAug 2, 2024 · CLNP023B12301 is a Phase 3 pivotal trial for registration of iptacopan in C3G. The study aims to determine the reduction in UPCR and improvement in eGFR in … coye yeager opelika al
Proteinuria University of Iowa Clinical Research and Trials
WebCLNP023B12301. Pediatrics Nephrology Kidney Disease Adult Subjects The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy. Subscribe to Glomerulopathy ... WebThe EU Clinical Trials Register currently displays 43188 clinical trials with a EudraCT protocol, of which 7144 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006). WebThe purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD. disney remote work jobs